[Metoclopramide as a risk factor for postprandial hyperglycemia in type 2 diabetes]. / Metoclopramida, factor de riesgo para hiperglucemia postprandial en diabetes tipo 2.

UNLABELLED: Diabetes mellitus is a pathology that has widely spread througout the world in the past decades. Postprandial hyperglycemia plays an important role in the progress of the disease due to the fact that increases the risk for cardiovascular events. This study's aim was to determine if the use of intravenous metoclopramide in patients with Diabetes Mellitus increases the postprandial glycemia. MATERIAL AND METHODS: A cohort of patients hospitalized with type 2 diabetes mellitus. Patients were classified as exposed (metoclopramide 10 mg IV) and not exposed, and glycemia preprandial and postprandial at 30, 60 and 120 minutes was measured. RESULTS: There were 80 patients in each group, and in both groups the general characteristics were homogeneous. The postprandial glycemia in the exposed group was higher at 30, 60, 90 and 120 minutes, being only statistically significant at 120 minutes postprandial (p = < 0,001). CONCLUSIONS: In conclusion, the use of intravenous metoclopramide is a risk factor to develop postprandial hyperglycemia in diabetic patients.

Metoclopramida, factor de riesgo para hiperglucemia postprandial en diabetes tipo 2 / Metoclopramide as a risk factor for postprandial hyperglycemia in type 2 diabetes

La diabetes mellitus (DM) es una patología que ha crecido ampliamente a nivel mundial en las ultimas décadas. La hiperglucemia postprandial (HP) ha tomado importancia en los últimos años, ya que se ha visto se relaciona de manera directa con un aumento en el riesgo de eventos cardiovasculares. A la fecha, no se ha determinado la asociación entre el empleo de metoclopramida y los niveles de glucemia postprandial. Material y métodos: Se realizó un estudio de tipo cohorte, con objeto de determinar si la metoclopramida es factor de riesgo para hiperglucemia postprandial. Se incluyeron pacientes diabéticos tipo 2, se catalogó a los pacientes en expuestos, aquellos manejados con metoclopramida preprandial 10 mg intravenosa (IV) y no expuestos, se determinó glucemia preprandial y 30, 60, 90 y 120 minutos postprandiales. Resultados: 80 pacientes por grupo se incluyeron siendo sus características basales similares. Las glucemia postprandial fue más elevada en aquellos tratados con metoclopramida que sin esta (p = < 0,001)). Conclusiones: La metoclopramida IV es un factor de riesgo para hiperglucemia postprandial en pacientes con diabetes mellitus tipo 2 (AU)

Diabetes mellitus is a pathology that has widely spread througout the world in the past decades. Postprandial hyperglycemia plays an important role in the progress of the disease due to the fact that increases the risk for cardiovascular events. This study's aim was to determine if the use of intravenous metoclopramide in patients with Diabetes Mellitus increases the postprandial glycemia. Material and methods: A cohort of patients hospitalized with type 2 diabetes mellitus. Patients were classified as exposed (metoclopramide 10 mg IV) and not exposed, and glycemia preprandial and postprandial at 30, 60 and 120 minutes was measured. Results: There were 80 patients in each group, and in both groups the general characteristics were homogeneous. The postprandial glycemia in the exposed group was higher at 30, 60, 90 and 120 minutes, being only statistically significant at 120 minutes postprandial (p = < 0,001). Conclusions: In conclusion, the use of intravenous metoclopramide is a risk factor to develop postprandial hyperglycemia in diabetic patients (AU)